The firm originally raised $55.5 million in the round in February 2018, and said investors added $30 million in December and another $20 million more recently.
The company plans to sell 7.9 million shares of common stock at $16 per share through its initial public offering.
In Nature this week: GWAS of cigarette smoking behaviors, set of gene expression predictors for schizophrenia, and more.
Harvard Medical School's George Church and his colleagues report in a preprint that they made more than 13,000 genome edits to a single cell.
The company has initial financing of $35 million, and has licensed its foundational SHERLOCK and INSPECTR technologies from the Broad and Harvard, respectively.
A WHO panel is calling for a global registry of human germline gene-editing projects, according to Stat News.
The agriculture company said it will use the technology it has licensed for new applications in crop editing and for research to bring new foods to market.
Japan is to release rules governing some gene-edited food, according to NHK World.
Eighteen researchers call for a temporary stop to all clinical uses of human germline editing in a piece appearing in Nature.
In Nature this week: benchmarking framework for variant calling, and more.
A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.
LiveScience reports that a novel mutation in the LPL gene was uncovered in three siblings with very high triglyceride levels.
The president of Nankai University is embroiled in a data manipulation scandal, the South China Morning Post reports.
In PNAS this week: cytotoxic CD4 T cell signature in supercentenarians, evolutionary history of beetles, and more.